Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s traded shares stood at 1.8 million during the last session, with the company’s beta value hitting 1.17. At the close of trading, the stock’s price was $8.75, to imply an increase of 4.04% or $0.34 in intraday trading. The ARQT share’s 52-week high remains $13.17, putting it -50.51% down since that peak but still an impressive 79.89% since price per share fell to its 52-week low of $1.76. The company has a valuation of $1.02B, with an average of 1.8 million shares in intraday trading volume over the past 10 days and average of 2.05 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Arcutis Biotherapeutics Inc (ARQT), translating to a mean rating of 1.29. Of 3 analyst(s) looking at the stock, 1 analyst(s) give ARQT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
After registering a 4.04% upside in the last session, Arcutis Biotherapeutics Inc (ARQT) has traded red over the past five days. The 5-day price performance for the stock is 0.34%, and -4.48% over 30 days. With these gigs, the year-to-date price performance is 170.90%. Short interest in Arcutis Biotherapeutics Inc (NASDAQ:ARQT) saw shorts transact 27.13 million shares and set a 14.56 days time to cover.
The extremes give us $18 and $51 for target low and target high price respectively. As such, ARQT has been trading -482.86% off suggested target high and -105.71% from its likely low.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
Looking at statistics comparing Arcutis Biotherapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Arcutis Biotherapeutics Inc (ARQT) shares are 3.31% up over the last 6 months, with its year-to-date growth rate higher than industry average at 57.67% against 17.50%. Revenue is forecast to grow 42.50% this quarter before jumping 50.00% for the next one. The rating firms project that company’s revenue will grow 178.90% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 37.62M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 47.81M.Earnings reports from the last fiscal year show that sales brought in 32.83M and 13.53M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 14.60% before jumping 253.50% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -48.07% for the past 5-year period. While 2024 is set for a 59.90% return in earnings, projections for the next 5 years are at 9.80% annually.
ARQT Dividends
Arcutis Biotherapeutics Inc has its next earnings report out on 2024-Nov-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
Arcutis Biotherapeutics Inc insiders hold 2.18% of total outstanding shares, with institutional holders owning 111.35% of the shares at 113.84% float percentage. In total, 111.35% institutions holds shares in the company, led by JENNISON ASSOCIATES LLC. As of 2024-06-30, the company held over 11.57 million shares (or 9.3712% of shares), all amounting to roughly $107.62 million.
The next major institution holding the largest number of shares is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares, or about 8.1021% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $93.04 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and PGIM Jennison Small Company Fd as the top two Mutual Funds with the largest holdings of the Arcutis Biotherapeutics Inc (ARQT) shares. Going by data provided on Sep 30, 2024 , SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 3.12 shares. This is just over 2.67% of the total shares, with a market valuation of $27.27 million. Data from the same date shows that the other fund manager holds a little less at 3.09, or 2.64% of the shares, all valued at about 27.0 million.
